WNK2 and neoplasm: Such agents include 1) vascular endothelial growth factor (VEGF) inhibitors, which are able to increase lymphocyte infiltration into tumors and reduce expression of Treg cells, 2) adenosine (P1) receptor inhibitors, which increase APC activation and reduce Treg cell expression, and 3) mitogen-activated protein kinase (MAPK) inhibitors, which promote tumor cell death and the presentation of tumor-associated antigens by enhancing MHC class I expression [12,20].